Meluha Life Sciences

Meluha Life Sciences is a clinical-stage biotechnology company which was incorporated on 2nd April 2009, developing novel and proprietary best-in-class therapies intended to extend and enhance the quality of human life. Our focal point is on researches, develops, manufactures and commercializes regenerative medicine products intended to improve the health and lives of patients and lower overall healthcare costs. Meluha Life Sciences lead investigational product, CHONDROGEN™ and CHONDROKIN™ is designed to reconstruct a patient's own knee cartilage to treat pain at the source and potentially prevent a patient's progression to osteoarthritis. We continue to advance our research and development ("R&D") by focusing on the treatment of medical conditions where there is significant unmet clinical need, and we are particularly focused on developing therapies in the regenerative medicine area.